Anemo Labs

Investor: Zinc, SFC Capital

London-based deep tech sensory digitization startup Anemo Labs has secured £700,000 in a Pre-Seed funding round co-led by venture capital firms Zinc and SFC Capital, with additional non-dilutive grant support from Innovate UK. Summary of transaction details: Value: £700,000 Pre-Seed investment (equity co-led by Zinc and SFC Capital, bolstered by Innovate UK grant funding). Sector: DeepTech & AI / MedTech / Sensory Digitization & Diagnostics. Advisor: Not disclosed. Key Entities: Target: Anemo Labs (Anemo Labs Ltd); Co-Lead Investors: Zinc (Zinc VC), SFC Capital; Grant Provider: Innovate UK; Key Founder: Koye Sodipo (Founder & CEO). Location: London, UK (HQ). Note: Founded in 2025 by CEO Koye Sodipo alongside a team of sensor chemistry PhDs and clinical advisors, Anemo Labs is pioneering the digitization of olfaction—the last remaining human sense yet to be effectively digitized into computer-readable data. The company is developing an artificial "Electronic Nose" (e-nose) hardware platform paired with deep learning models to detect, isolate, and classify disease-related Volatile Organic Compounds (VOCs) emitted from biological samples such as urine. Because cellular changes and metabolic shifts emit subtle chemical scent signatures long before physical symptoms appear, Anemo’s non-invasive e-nose provides a continuous, passive screening mechanism for early-stage conditions including Urinary Tract Infections (UTIs) and various cancers. A key technological barrier in olfactory AI is training data; Anemo overcomes this via an automated in-house sampling platform capable of capturing and labeling up to 5,000 scent samples per day. In early performance benchmarking using the industry-standard Sniffin' Sticks protocol, Anemo's classification models achieved an 84.15% accuracy rate across a dozen distinct scent categories. This £700,000 Pre-Seed injection will be deployed to refine core sensor chemistry, expand the automated smell labeling data pipeline, and advance clinical validation trials alongside NHS and academic healthcare partners.